$CNCL
CANCER CAPITAL CORP

2022 Q4 Form 10-Q Financial Statement

#000155479522000364 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.749K $6.315K
YoY Change -56.47%
Operating Profit -$2.749K -$6.315K
YoY Change -56.47%
Interest Expense $2.506K $1.880K
YoY Change 33.3%
% of Operating Profit
Other Income/Expense, Net -$5.448K -$4.663K
YoY Change 16.83%
Pretax Income -$8.197K -$10.98K
YoY Change -25.33%
Income Tax
% Of Pretax Income
Net Earnings -$8.197K -$10.98K
YoY Change -25.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 6.150M shares 6.150M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $22.06K $21.85K $1.383K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.06K $21.85K
YoY Change 35472.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $22.06K $21.85K
Total Long-Term Assets $0.00 $0.00
Total Assets $22.06K $21.85K
YoY Change 35472.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $433.7K $421.6K
YoY Change 17.46%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $433.7K $421.6K
Total Long-Term Liabilities
Total Liabilities $433.7K $421.6K
YoY Change 17.46%
SHAREHOLDERS EQUITY
Retained Earnings -$464.8K -$453.0K
YoY Change 10.06%
Common Stock $6.150K $6.150K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$411.6K -$399.8K -$361.6K
YoY Change
Total Liabilities & Shareholders Equity $22.06K $21.85K
YoY Change 35472.58%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$8.197K -$10.98K
YoY Change -25.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84106
dei City Area Code
CityAreaCode
(801)
dei Local Phone Number
LocalPhoneNumber
323-2395
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-32363
dei Entity Registrant Name
EntityRegistrantName
CANCER CAPITAL CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Central Index Key
EntityCentralIndexKey
0001130889
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1803648
dei Entity Address Address Line1
EntityAddressAddressLine1
2157 S. Lincoln Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
dei Amendment Flag
AmendmentFlag
false
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6150000 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21854 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
21854 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
62 usd
CY2022Q3 us-gaap Assets
Assets
21854 usd
CY2021Q4 us-gaap Assets
Assets
62 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
10500 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
6000 usd
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
149125 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
145125 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
125275 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
97275 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
74698 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
65950 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
62041 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
54844 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
421639 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
369194 usd
CY2022Q3 us-gaap Liabilities
Liabilities
421639 usd
CY2021Q4 us-gaap Liabilities
Liabilities
369194 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452985 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422332 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-399785 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-369132 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21854 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2749 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6315 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14709 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15515 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2749 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6315 usd
us-gaap Operating Expenses
OperatingExpenses
14709 usd
us-gaap Operating Expenses
OperatingExpenses
15515 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2749 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6315 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14709 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15515 usd
CY2022Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2942 usd
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2783 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
8747 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
8349 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
2506 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
1880 usd
us-gaap Interest Expense
InterestExpense
7197 usd
us-gaap Interest Expense
InterestExpense
5380 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5448 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4663 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15944 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13729 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8197 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10978 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30653 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29244 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8197 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10978 usd
us-gaap Net Income Loss
NetIncomeLoss
-30653 usd
us-gaap Net Income Loss
NetIncomeLoss
-29244 usd
CY2022Q3 CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CY2021Q3 CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CY2022Q3 CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CY2021Q3 CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-332340 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9894 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-342234 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8372 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-350606 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10978 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-361584 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-369132 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14198 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-383330 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8258 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-391588 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8197 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-399785 usd
us-gaap Net Income Loss
NetIncomeLoss
-30653 usd
us-gaap Net Income Loss
NetIncomeLoss
-29244 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
4500 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
4500 usd
us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
8748 usd
us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
8349 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
7197 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
5380 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10208 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11015 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
28000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11700 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11700 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21792 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
685 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
698 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21854 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1383 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
4500 usd
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
4500 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
10500 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
6000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
28000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11700 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
125275 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
97275 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
62041 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
54844 usd

Files In Submission

Name View Source Status
0001554795-22-000364-index-headers.html Edgar Link pending
0001554795-22-000364-index.html Edgar Link pending
0001554795-22-000364.txt Edgar Link pending
0001554795-22-000364-xbrl.zip Edgar Link pending
cncl-20220930.xsd Edgar Link pending
cncl1103form10q.htm Edgar Link pending
cncl1103form10qexh31_1.htm Edgar Link pending
cncl1103form10qexh31_2.htm Edgar Link pending
cncl1103form10qexh32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cncl-20220930_lab.xml Edgar Link unprocessable
cncl-20220930_cal.xml Edgar Link unprocessable
cncl-20220930_def.xml Edgar Link unprocessable
cncl-20220930_pre.xml Edgar Link unprocessable
cncl1103form10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable